CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF 
MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The Member States shall ensure that all conditions or restrictions with regard to the safe and effective 
use of the medicinal product described below are implemented: 
The  Marketing  Authorisation  Holder  (MAH)  shall  ensure  that,  at  launch,  all  physicians  who  are 
expected to prescribe/use NovoSeven are provided with an Educational pack containing the following: 
• 
• 
Physician information pack 
Patient information pack 
Both  information  packs  are  to  be  used  as  part  of  an  educational  plan  provided  to  minimise  risk  of 
medication  errors  that  may  be  associated  with  the  change  in  concentration  of  the  new  Novoseven 
formulation.  
The physician information pack should contain the following: 
• 
Summary leaflet of the product features and reconstitution guide, including highlighted changes 
that have been made for the new formulation of NovoSeven. 
Educational slide kit 
Dosing reference card 
Question & Answer booklet 
Patient information pack 
Letter to healthcare professionals 
The physician information should contain the following key elements: 
• 
Clear demarcation of the new formulation of NovoSeven from original NovoSeven, with clear 
descriptions of any differences in the vial sizes, colour codes and dosing and reconstitution 
instructions  
Clear information about their difference in concentration. 
Information about the potential safety risks of errors in dosing calculation resulting from the 
confusion between the two formulations and its possible clinical consequences (e.g. potential 
for thrombotic risk if overdose). 
Encouragement to report medications errors and their causes and consequences. 
The patient information pack to be used by healthcare professionals in the education of the patients 
should contain the same above described key elements. 
The Marketing Authorisation Holder must implement this educational plan nationally, prior to marketing, 
and as agreed with the competent authorities in the Member States. 
2
 
 
 
 
 
 
 
 
 
 
